Shandong Lukang PharmaceuticalLtd Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Kun Dong

Chief executive officer

CN¥900.5k

Total compensation

CEO salary percentage	n/a
CEO tenure	3yrs
CEO ownership	0.03%
Management average tenure	8.2yrs
Board average tenure	5yrs

Recent management updates

Recent updates

Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) Surges 26% Yet Its Low P/E Is No Reason For Excitement

May 06

Shandong Lukang PharmaceuticalLtd's (SHSE:600789) Solid Profits Have Weak Fundamentals

Apr 03

CEO

Kun Dong (53 yo)

3yrs

Tenure

CN¥900,500

Compensation

Mr. Kun Dong is General Manager and Director at Shandong Lukang Pharmaceutical Co.,Ltd since May 19, 2021. He was Deputy General Manager of Shandong Lukang Pharmaceutical Co.,Ltd.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kun Dong	GM & Director	3yrs	CN¥900.50k	0.034% CN¥ 2.9m
Li Li	CFO & Director	8.2yrs	CN¥778.10k	0.043% CN¥ 3.7m
Lixin Tian	Secretary of the Board of Directors	23.3yrs	CN¥494.00k	0.031% CN¥ 2.7m
Haifeng Cao	Deputy General Manager	no data	CN¥737.00k	0.015% CN¥ 1.3m
Defeng He	Deputy General Manager	no data	CN¥727.60k	0.015% CN¥ 1.3m

8.2yrs

Average Tenure

53yo

Average Age

Experienced Management: 600789's management team is seasoned and experienced (8.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kun Dong	GM & Director	3yrs	CN¥900.50k	0.034% CN¥ 2.9m
Li Li	CFO & Director	3yrs	CN¥778.10k	0.043% CN¥ 3.7m
Jie Zhang	Director	no data	CN¥692.30k	0.034% CN¥ 3.0m
Cheng Yong Zhang	Director	2yrs	no data	no data
Peng Xin	Chairman	6yrs	CN¥1.14m	0.064% CN¥ 5.6m
Ke Chun Cong	Director	15.1yrs	no data	no data
Chengtong Liu	Vice Chairman of the Supervisory Board	9.9yrs	no data	no data
Shuai Yang	Employee Representative Member of Supervisory Board	11.1yrs	no data	no data
Haodong Qi	Independent Director	3yrs	CN¥100.00k	no data
Zhi Yong Yang	Chairman of the Supervisory Board	6yrs	no data	no data
Zi Xin Deng	Independent Director	3yrs	CN¥100.00k	no data
Tao Zhang	Employee Representative Supervisor	5yrs	no data	no data

5.0yrs

Average Tenure

51.5yo

Average Age

Experienced Board: 600789's board of directors are considered experienced (5 years average tenure).

Shandong Lukang PharmaceuticalLtd Management

Management criteria checks 4/4

Key information

Recent management updates

Shandong Lukang Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 23, 2024

Less than half of directors are independent

Recent updates

Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.05 in 1Q 2023)

Shandong Lukang PharmaceuticalLtd's (SHSE:600789) Solid Profits Have Weak Fundamentals

Shandong Lukang Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 23, 2024

Shandong Lukang Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 23, 2024

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.16 in FY 2022)

Investor sentiment deteriorates as stock falls 17%

Shandong Lukang Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 09, 2024

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.023 in 3Q 2022)

Shandong Lukang Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.029 in 2Q 2022)

Shandong Lukang Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Aug 19, 2023

First quarter 2023 earnings released: EPS: CN¥0.05 (vs CN¥0.05 in 1Q 2022)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.023 (vs CN¥0.018 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.029 (vs CN¥0.028 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.05 in 1Q 2021)

Full year 2021 earnings released: EPS: CN¥0.09 (vs CN¥0.26 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.018 (vs CN¥0.002 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.028 (vs CN¥0.19 in 2Q 2020)

Upcoming dividend of CN¥0.055 per share

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.14 in FY 2019)

New 90-day low: CN¥7.16

Investor sentiment deteriorated over the past week

New 90-day low: CN¥8.51

New 90-day low: CN¥8.81

Third quarter earnings released

Shandong Lukang Pharmaceutical Co.,Ltd. to Report Q3, 2020 Results on Oct 31, 2020

First half earnings released

Shandong Lukang Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 29, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age